So far, humans have been at a loss how to deal with Alzheimer's disease, and β-amyloid levels in the brain are now only accurately assessed by PET imaging (positron emission computed tomography) or by measuring β-amyloid levels in the cerebrospinal fluid, The medical community is in urgent need of a more economical, less invasive diagnostic tool.
Using a combination of immunoprecipitation and mass spectrometry, the Japanese National Institute of Geriatrics and Geriatrics researchers measured the levels of multiple amyloid-β-related peptides in the blood and tested them in two separate data sets Methods - One is a discovery dataset of 121 samples from Japan and the other is a validation dataset of 252 samples from Australia Both samples of the dataset were from humans and both included normal cognition Individuals with mild cognitive impairment and people with Alzheimer's disease.Studies have shown that accurate prediction of individual brains through the proportion of different beta-amyloid-related peptides and an integrated 'score' β-Amyloid deposition levels.
These plasma biomarkers are less invasive, more economical and more expansive than current technologies and are expected to be widely used clinically.Currently, clinical trials to improve the course of Alzheimer's disease are generally performed on patients who are at The earliest patients with the most effective disease, and these biomarkers can help doctors determine the most suitable clinical trial participants, so in the future can be used to identify individuals with high risk of Alzheimer's disease.
The research team also suggested that the effectiveness of the results as a disease surveillance tool still needs further evaluation, especially before it is widely used in clinical practice. More effective research should be carried out.